The VERIFY trial
The VERIFY investigators will reveal whether the durability of glycemic control is improved by adding the dipeptidyl peptidase-4 inhibitor vildagliptin to the standard first-line treatment of metformin in people with type 2 diabetes who are drug-naïve or have taken metformin for less than 1 month.
Amrit Lamba discusses how the findings of VERIFY may influence how primary care practitioners will approach first-line treatment of people with type 2 diabetes (4:32).
Results from the VERIFY trial were presented at the 55th EASD Annual Meeting (EASD 2019):
Vildagliptin Efficacy in combination with metfoRmIn For earlY treatment of T2DM (VERIFY)
Wednesday, September 18, 13:15–14:15. Joslin Hall, Vilanova Hall, Fira Barcelona Gran Via, Spain
Session Chair: C. Mathieu, Belgium
- Introduction and background. C. Mathieu, Belgium
- Rationale, design, methods. M. Stumvoll, Germany
- Main results and safety. D. R. Matthews, UK
- Summary and clinical implications. S. Del Prato, Italy
- Commentary. C. J. Bailey, UK
What our Editorial Board said:
Vildagliptin provides a durable way of ensuring glucose lowering in a safe and well tolerated manner. Sustainability is the foundation of the glycemic pyramid (sufficiency, safety, security), and VERIFY verifies the ability of vildaglitpin plus metformin combination to achieve these aims of therapy.